Molecular mechanisms and therapeutic interventions in sarcopenia
| Autor: | Eun Soo Kwon, Ki Sun Kwon, Sung Sup Park |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Aging Sarcopenia lcsh:Diseases of the musculoskeletal system Psychological intervention Disease Review Article Bioinformatics Muscle hypertrophy 03 medical and health sciences Atrophy medicine Mechanisms Myogenesis business.industry Autophagy Skeletal medicine.disease musculoskeletal system body regions 030104 developmental biology Therapy Stem cell lcsh:RC925-935 business human activities |
| Zdroj: | Osteoporosis and Sarcopenia Osteoporosis and Sarcopenia, Vol 3, Iss 3, Pp 117-122 (2017) |
| ISSN: | 2405-5263 2405-5255 |
| Popis: | Sarcopenia is the degenerative loss of muscle mass and function with aging. Recently sarcopenia was recognized as a clinical disease by the International Classification of Disease, 10th revision, Clinical Modification. An imbalance between protein synthesis and degradation causes a gradual loss of muscle mass, resulting in a decline of muscle function as a progress of sarcopenia. Many mechanisms involved in the onset of sarcopenia include age-related factors as well as activity-, disease-, and nutrition-related factors. The stage of sarcopenia reflecting the severity of conditions assists clinical management of sarcopenia. It is important that systemic descriptions of the disease conditions include age, sex, and other environmental risk factors as well as levels of physical function. To develop a new therapeutic intervention needed is the detailed understanding of molecular and cellular mechanisms by which apoptosis, autophagy, atrophy, and hypertrophy occur in the muscle stem cells, myotubes, and/or neuromuscular junction. The new strategy to managing sarcopenia will be signal-modulating small molecules, natural compounds, repurposing of old drugs, and muscle-specific microRNAs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|